| Oct 21 |
Kenvue: Starboard Pushes for a Bold Turnaround
|
| Oct 21 |
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
|
| Oct 21 |
J&J’s Ketamine-Derived Drug Is Taking Off
|
| Oct 21 |
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
|
| Oct 20 |
The 'Texas two-step' is back as J&J tries to shed talc lawsuits for a third time
|
| Oct 19 |
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
|
| Oct 19 |
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
|
| Oct 19 |
Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth
|
| Oct 18 |
Johnson & Johnson (JNJ): Growth Prospects Enhanced by Key Acquisitions and Approvals
|
| Oct 18 |
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
|
